A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare

Harubumi Kato, Toshihide Nishimura, Takashi Hirano, Masaharu Nomura, Hiromasa Tojo, Kiyonaga Fujii, Takeshi Kawamura, Sayaka Mikami, Makoto Kihara, Yasuhiko Bando, Masahiro Tsuboi, Norihiko Ikeda, György Marko-Varga

Research output: Contribution to journalDebate/Note/Editorial

7 Citations (SciVal)

Abstract

In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.
Original languageEnglish
Pages (from-to)51-57
JournalJournal of Proteome Research
Volume10
Issue number1
DOIs
Publication statusPublished - 2011

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Analytical Chemistry (S/LTH) (011001004)

Subject classification (UKÄ)

  • Analytical Chemistry

Keywords

  • lung cancer
  • diagnosis and treatment
  • proteomic study
  • healthcare

Fingerprint

Dive into the research topics of 'A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare'. Together they form a unique fingerprint.

Cite this